Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The peptidoglycan pentaglycine cross-bridge is a structural element of the bacterial cell wall, found predominantly in Gram-positive bacteria such as *Staphylococcus aureus*. It consists of a short peptide chain of five glycine residues that links the peptide stems attached to N-acetylmuramic acid residues in adjacent glycan strands of peptidoglycan. This bridge cross-links the third amino acid of one stem peptide (usually L-lysine) to the fourth D-alanine of another peptide stem, resulting in a highly crosslinked, mesh-like sacculus that protects bacteria against osmotic lysis and environmental stresses[2][4][6][9]. The pentaglycine cross-bridge is synthesized by a dedicated set of enzymes, including FemX, FemA, and FemB, and is essential for staphylococcal cell wall architecture and viability[3]. It serves as a specific docking site and substrate for enzymes like lysostaphin, which cleave these bridges, leading to cell wall disruption—a mechanism exploited for antibacterial therapy[5][3]. Since this structure is present in pathogenic staphylococci but rare or absent in human cells and many commensal bacteria, it represents an effective, selective therapeutic target for anti-staphylococcal drugs[3][5].
Cleavage of the pentaglycine cross-bridge by endopeptidase; Disruption of peptidoglycan mesh integrity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidoglycan pentaglycine cross-bridge.